Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials

Conclusions: Our meta-analysis of randomized controlled studies showed that pCR rates are significantly higher in the concurrent use of trastuzumab and anthracycline-based NAC compared with the non-concurrent use of trastuzumab and anthracycline-based NAC for certain HER2-positive breast cancer, meanwhile without significant increase of the cardiotoxicity.

Source: Journal of Cancer - December 14, 2018 Category: Cancer & Oncology Authors: Yu-tuan Wu, Zhou Xu, Bilal Arshad, Jiu-song Wu, Ke Zhang, He Wu, Xin Li, Hao Li, Ying-cun Li, Zhong-liang Wang, Kai-nan Wu, Ling-quan Kong Tags: Research Paper Source Type: research